CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-2.15%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.76B
AUM Growth
+$2.76B
(+6.6%)
Cap. Flow
+$282M
Cap. Flow
% of AUM
10.19%
Top 10 Holdings %
Top 10 Hldgs %
57.66%
Holding
45
New
8
Increased
20
Reduced
5
Closed
7
Top Buys
| 1 |
Viatris
VTRS
|
$76.2M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$59.6M |
| 3 |
Medtronic
MDT
|
$55.5M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$51.4M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$49.1M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$98.8M |
| 2 |
Merck
MRK
|
$82.1M |
| 3 |
GSK
GSK
|
$65.3M |
| 4 |
Biogen
BIIB
|
$60M |
| 5 |
WBA
Walgreens Boots Alliance
WBA
|
$49.2M |
Sector Composition
| 1 | Healthcare | 95.18% |
| 2 | Technology | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceuticals
TEVA
$21.1B
| $25.8M | 0.93% |
2,750,000
| – | – |
|
27
Inogen
INGN
$216M
| $24.3M | 0.88% |
750,000
+550,000
| +275% | +$17.8M |
|
28
Select Medical
SEM
$1.61B
| $24M | 0.87% |
+1,000,000
| New | +$24M |
|
29
Nektar Therapeutics
NKTR
$568M
| $21.6M | 0.78% |
4,000,000
+250,000
| +7% | +$1.35M |
|
30
Collegium Pharmaceutical
COLL
$1.22B
| $21.4M | 0.77% |
1,050,000
| – | – |
|
31
Zymeworks
ZYME
$1.12B
| $13.1M | 0.47% |
2,000,000
+1,200,000
| +150% | +$7.86M |
|
32
Puma Biotechnology
PBYI
$254M
| $11.5M | 0.42% |
4,000,000
+1,950,000
| +95% | +$5.62M |
|
33
Glaukos
GKOS
$5.5B
| $10.8M | 0.39% |
187,022
+112,022
| +149% | +$6.48M |
|
34
Exelixis
EXEL
$10.1B
| $6.8M | 0.25% |
+300,000
| New | +$6.8M |
|
35
Evolent Health
EVH
$1.12B
| $5.99M | 0.22% |
+185,400
| New | +$5.99M |
|
|
SDC
36
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $2.59M | 0.09% |
1,000,000
+575,000
| +135% | +$1.49M |
|
|
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
| $2.32M | 0.08% |
+262,900
| New | +$2.32M |
|
38
Alkermes
ALKS
$4.78B
| – | – |
-1,300,000
| Closed | -$30.2M |
|
|
39
Biogen
BIIB
$19.4B
| – | – |
-250,000
| Closed | -$60M |
|
40
InnovAge Holding
INNV
$517M
| – | – |
-350,000
| Closed | -$1.75M |
|
41
Ironwood Pharmaceuticals
IRWD
$214M
| – | – |
-3,000,000
| Closed | -$35M |
|
42
Novartis
NVS
$245B
| – | – |
0
| – | – |
|
43
Theravance Biopharma
TBPH
$699M
| – | – |
-500,000
| Closed | -$5.53M |
|
|
44
Vertex Pharmaceuticals
VRTX
$100B
| – | – |
-450,000
| Closed | -$98.8M |
|
|
TECX
45
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| – | – |
-1,633,333
| Closed | -$6.29M |
|